Autor: Firma TolerogenixX

TolerogenixX Receives Approval to Start Phase IIb Trial for its Immune Tolerance-Inducing MIC-Lx Cell Therapy

28. März 202228. März 2022 Firma TolerogenixXAllgemeinbiopsy, cell, cells, centric, ckd, clinical, graft, hla, lupus, patients, production, therapy, tolerogenixx, transplant, with

Multi-centric clinical study in patients with stage 5 chronic kidney disease (CKD) receiving a living donor kidney Study of MIC-Lx cell treatment, a potentially curative approach to achieve sustained immune tolerance in transplanted and autoimmune patients as shown in Mehr

TolerogenixX Reports Positive Phase Ib Data of its Lead Product to Combat Transplant Rejection

11. Mai 20207. April 2021 Firma TolerogenixXAllgemeincell, cells, clinical, endpoint, graft, hla, kidney, lupus, mics, patients, sam?, therapy, transplant, varicella, with

. – Product shows excellent safety and tolerability – Enables long-term reduction of standard medications and side effects while maintaining immune tolerance and transplant function – Findings endorsed by third-party experts TolerogenixX GmbH, a biopharmaceutical company developing personalized, cellular therapies Mehr